Navigation Links
Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord
Date:10/18/2007

p>
  • Death and disability rates among patients were highest in those who had a defined brain dysfunction, such as cognitive impairment, stroke and disease of the large blood vessels on angiography.

  • The annual incidence rate of primary central nervous system vasculitis was 2.4 cases per 1 million people.

Collaboration and Support

Other members of the Mayo Clinic research team include Carlo Salvarani, M.D.; Kenneth Calamia, M.D.; Teresa Christianson; Stephen Weigand; Dylan Miller, M.D.; Caterina Giannini, M.D.; James Meschia, M.D.; John Huston III, M.D.; and Gene Hunder, M.D. Their work was supported with grants from Mayo Foundation for Medical Education and Research.


'/>"/>

Contact: Carol Lammers
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Vivakor Announces New Acquisition Strategy 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 1Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 2SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 1SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 2SIUE School of Pharmacy Launches Collaborative Site for Pain Palliative Care Pharmacy 58620 3